Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Neurocrine Biosciences Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.16 (market cap $12.87B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF and Neurocrine Biosciences Inc are close in size by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EMB | NBIX | |
|---|---|---|
Market Cap | $12.87B | $14.36B |
Volume | 14,946,002 | 1,237,180 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $185.50 |
52-Week Low | $90.14 | $123.10 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.13 with a slight 0.39% daily gain, though technical indicators signal bearish momentum with moving averages and ADX showing sell signals. The stock faces resistance near $91-92 levels while finding support around $90. Recent dividend announcements for H2-2026 provide income appeal, but fundamental metrics remain undisclosed in current data.
The outlook appears cautious given bearish technical signals and limited fundamental visibility. Investment opportunity rests on income generation through scheduled dividends, while risks include technical weakness and potential market volatility from rising bond yields affecting fixed-income alternatives.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
